The estimated Net Worth of Jennifer Michaelson is at least $4.19 Миллион dollars as of 5 September 2024. Dr Michaelson owns over 8,000 units of Cullinan Oncology stock worth over $2,084,637 and over the last 4 years he sold CGEM stock worth over $2,108,477.
Dr has made over 21 trades of the Cullinan Oncology stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 8,000 units of CGEM stock worth $144,720 on 5 September 2024.
The largest trade he's ever made was selling 63,606 units of Cullinan Oncology stock on 6 May 2024 worth over $1,796,870. On average, Dr trades about 4,627 units every 41 days since 2021. As of 5 September 2024 he still owns at least 115,942 units of Cullinan Oncology stock.
You can see the complete history of Dr Michaelson stock trades at the bottom of the page.
Dr. Jennifer Michaelson Ph.D. is the Chief Devel. Officer of Biologics at Cullinan Oncology.
Dr D is 53, he's been the Chief Devel. Officer of Biologics of Cullinan Oncology since . There are 4 older and 2 younger executives at Cullinan Oncology. The oldest executive at Cullinan Oncology, LLC is Dr. Patrick A. Baeuerle Ph.D., 63, who is the Co-Founder & Acting Chief Scientific Officer of Biologics.
Jennifer's mailing address filed with the SEC is C/O CULLINAN THERAPEUTICS, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142.
Over the last 4 years, insiders at Cullinan Oncology have traded over $29,405,190 worth of Cullinan Oncology stock and bought 2,950,136 units worth $38,299,215 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke и Morana Jovan Embiricos. On average, Cullinan Oncology executives and independent directors trade stock every 14 days with the average trade being worth of $914,589. The most recent stock trade was executed by Jennifer Michaelson on 5 September 2024, trading 8,000 units of CGEM stock currently worth $144,720.
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Cullinan Oncology executives and other stock owners filed with the SEC include: